Tailoring antiplatelet therapy in older patients with coronary artery disease

References

• Damluji AA, Huang J, Bandeen‐Roche K, Forman DE, Gerstenblith G, Moscucci M, Resar JR, Varadhan R, Walston JD, Segal JB, et al. Frailty among older adults with acute myocardial infarction and outcomes from percutaneous coronary interventions. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2019 Aug 31;8(17):e013686. doi:10.1161/JAHA.119.013686.
   Google Scholar
• Damluji AA, Forman DE, Wang TY, Chikwe J, Kunadian V, Rich MW, Young BA, Page RL, DeVon HA, Alexander KP, et al. Management of acute coronary syndrome in the older adult population: a scientific statement from the American Heart association. Circulation. 2023 Jan 17;147(3):e32–10. doi:10.1161/CIR.0000000000001112.
   PubMed Web of Science ®Google Scholar
• Ratcovich H, Beska B, Mills G, Holmvang L, Adams-Hall J, Stevenson H, Veerasamy M, Wilkinson C, Kunadian V, Back M, et al. Five-year clinical outcomes in patients with frailty aged ≥75 years with non-ST elevation acute coronary syndrome undergoing invasive management. Eur Heart J Open. 2022 May;2(3):oeac035. doi:10.1093/ehjopen/oeac035.
   PubMedGoogle Scholar
• Beska B, Mills GB, Ratcovich H, Wilkinson C, Damluji AA, Kunadian V. Impact of multimorbidity on long-term outcomes in older adults with non-ST elevation acute coronary syndrome in the North East of England: a multi-centre cohort study of patients undergoing invasive care. BMJ Open. 2022 Jul 26;12(7):e061830. doi:10.1136/bmjopen-2022-061830.
   PubMed Web of Science ®Google Scholar
• Beska B, Coakley D, MacGowan G, Adams-Hall J, Wilkinson C, Kunadian V. Frailty and quality of life after invasive management for non-ST elevation acute coronary syndrome. Heart Br Card Soc. 2022 Feb;108(3):203–11. doi:10.1136/heartjnl-2021-319064.
   PubMed Web of Science ®Google Scholar
• Chung KJNC, Wilkinson C, Veerasamy M, Kunadian V. Frailty scores and their utility in older patients with cardiovascular disease. Interv Cardiol Lond Engl. 2021 Apr;16:e05. doi:10.15420/icr.2020.18.
   PubMedGoogle Scholar
• Schoenenberger AW, Radovanovic D, Stauffer JC, Windecker S, Urban P, Eberli FR, Stuck AE, Gutzwiller F, Erne P. Age-related differences in the use of guideline-recommended medical and interventional therapies for acute coronary syndromes: a cohort study. J Am Geriatr Soc. 2008 Mar;56(3):510–6. doi:10.1111/j.1532-5415.2007.01589.x.
   PubMed Web of Science ®Google Scholar
• Damluji AA, Resar JR, Gerstenblith G, Gross AL, Forman DE, Moscucci M. Temporal trends of percutaneous coronary interventions in older adults with acute myocardial infarction. Circ Cardiovasc Interv. 2019 May;12(5):e007812. doi:10.1161/CIRCINTERVENTIONS.119.007812.
   PubMed Web of Science ®Google Scholar
• Elbadawi A, Elgendy IY, Ha LD, Mahmoud K, Lenka J, Olorunfemi O, Reyes A, Ogunbayo GO, Saad M, Abbott JD, et al. National trends and outcomes of percutaneous coronary intervention in patients ≥70 years of age with acute coronary syndrome (from the national inpatient sample database). Am J Cardiol. 2019 Jan 1;123(1):25–32. doi:10.1016/j.amjcard.2018.09.030.
   PubMed Web of Science ®Google Scholar
• Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019 Jul 16;140(3):240–61. doi:10.1161/CIRCULATIONAHA.119.040167.
   PubMed Web of Science ®Google Scholar
• Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong M-K, Kim H-S, Colombo A, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet Lond Engl. 2017 Mar 11;389(10073):1025–34. doi:10.1016/S0140-6736(17)30397-5.
   Google Scholar
• Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet J-P, Falk V, Head SJ, et al., 2018 ESC/EACTS Guidelines on myocardial revascularization, EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2019;14(14):1435–534. 2019 Feb 20. doi:10.4244/EIJY19M01_01.
   Google Scholar
• Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al., ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, Eur Heart J. 2020;42(14):1289–367. 2021 Apr 7. doi:10.1093/eurheartj/ehaa575.
   Web of Science ®Google Scholar
• Sinnaeve PR, Adriaenssens T. Dual antiplatelet therapy De-escalation strategies. Am J Cardiol. 2021 Apr 1;144(Suppl 1):S23–31. doi:10.1016/j.amjcard.2020.12.020.
   PubMedGoogle Scholar
• Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ. 2018 Oct 2;363:k3793. doi:10.1136/bmj.k3793.
   PubMedGoogle Scholar
• De Luca G, Damen SA, Camaro C, Benit E, Verdoia M, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2019 Dec 6;15(11):e990–8. doi:10.4244/EIJ-D-19-00539.
   Google Scholar
• Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim S-H, Jeong J-O, Bae J-H, Kim B-O, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet Lond Engl. 2018 Mar 31;391(10127):1274–84. doi:10.1016/S0140-6736(18)30493-8.
   Google Scholar
• Misumida N, Abo-Aly M, Kim SM, Ogunbayo GO, Abdel-Latif A, Ziada KM. Efficacy and safety of short-term dual antiplatelet therapy (≤6 months) after percutaneous coronary intervention for acute coronary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Cardiol. 2018 Nov;41(11):1455–62. doi:10.1002/clc.23075.
   PubMed Web of Science ®Google Scholar
• Armstrong PCJ, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost JTH. 2011 Mar;9(3):552–61. doi:10.1111/j.1538-7836.2010.04160.x.
   PubMed Web of Science ®Google Scholar
• Traby L, Kollars M, Kaider A, Eichinger S, Wolzt M, Kyrle PA. Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects. J Thromb Haemost JTH. 2016 Feb;14(2):273–81. doi:10.1111/jth.13216.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045–57. doi:10.1056/NEJMoa0904327.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann F-J, Ardissino D, De Servi S, Murphy SA, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001–15. doi:10.1056/NEJMoa0706482.
   PubMed Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im E-S, Jeong J-O, Cho BR, Oh SK, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019 Jun 25;321(24):2428–37. doi:10.1001/jama.2019.8146.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019 Jun 25;321(24):2414–27. doi:10.1001/jama.2019.8145.
   PubMed Web of Science ®Google Scholar
• Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her A-Y, Cho S, Jeon DW, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020 Jun 16;323(23):2407–16. doi:10.1001/jama.2020.7580.
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019 Nov 21;381(21):2032–42. doi:10.1056/NEJMoa1908419.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es, G.A., McFadden, E.P., Onuma, Y., van Meijeren, C., et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet Lond Engl. 2018 Sep 15;392(10151):940–9.
   Google Scholar
• Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang CC, Kogame N, Spitzer E, Buszman PE, van Geuns RJM, Valkov V, et al. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2020 Apr 3;15(18):e1605–14. doi:10.4244/EIJ-D-19-00699.
   Google Scholar
• Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, Suwa S, Isawa T, Domei T, Yamaji K, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiol. 2022 Apr 1;7(4):407–17. doi:10.1001/jamacardio.2021.5244.
   PubMed Web of Science ®Google Scholar
• Onuma Y, Kimura T, Räber L, Magro M, Girasis C, van Domburg R, Windecker, S., Mitsudo, K., Serruys, P.W., et al. Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan: a patient-level data analysis of the bern-rotterdam and j-cypher registries. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2015 Sep;11(5):533–40.
   Google Scholar
• Koo BK, Kang J, Park KW, Rhee TM, Yang HM, Won KB, Rha S-W, Bae J-W, Lee NH, Hur S-H, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet Lond Engl. 2021 Jun 26;397(10293):2487–96. doi:10.1016/S0140-6736(21)01063-1.
   Google Scholar
• Kang J, Park KW, Lee H, Hwang D, Yang HM, Rha SW, Bae J-W, Lee NH, Hur S-H, Han J-K, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023 Jan 10;147(2):108–17. doi:10.1161/CIRCULATIONAHA.122.062770.
   PubMed Web of Science ®Google Scholar
• Généreux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, Neumann F-J, Metzger DC, Henry TD, Cox DA, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015 Sep 1;66(9):1036–45. doi:10.1016/j.jacc.2015.06.1323.
   PubMed Web of Science ®Google Scholar
• Escaned J, Cao D, Baber U, Nicolas J, Sartori S, Zhang Z, Dangas G, Angiolillo DJ, Briguori C, Cohen DJ, et al. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021 Dec 1;42(45):4624–34. doi:10.1093/eurheartj/ehab702.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Cao D, Baber U, Sartori S, Zhang Z, Dangas G, Mehta S, Briguori C, Cohen DJ, Collier T, et al. Impact of age on the safety and efficacy of ticagrelor monotherapy in patients undergoing PCI. JACC Cardiovasc Interv. 2021 Jul 12;14(13):1434–46. doi:10.1016/j.jcin.2021.04.043.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, et al. Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. Cardiovasc Interv And Ther. 2021 Jan;36(1):91–103. doi:10.1007/s12928-020-00651-9.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, Ozaki Y, Morice M-C, Chevalier B, Onuma Y, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021 Oct 28;385(18):1643–55. doi:10.1056/NEJMoa2108749.
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Murphy SA, Sabatine MS. The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Circulation. 2020 Aug 11;142(6):538–45. doi:10.1161/CIRCULATIONAHA.120.046251.
   PubMed Web of Science ®Google Scholar
• Roule V, Lemaitre A, Pommier W, Bignon M, Sabatier R, Blanchart K, Beygui F. Safety and efficacy of very short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy in older patients undergoing percutaneous coronary intervention: meta-analysis of randomised controlled trials. Age Ageing. 2021 Jun 28;50(4):1102–7. doi:10.1093/ageing/afab047.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, Bonnet G, Fourcade L, Mouret JP, Lambert M, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017 Nov 1;38(41):3070–8. doi:10.1093/eurheartj/ehx175.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet Lond Engl. 2017 Oct 14;390(10104):1747–57. doi:10.1016/S0140-6736(17)32155-4.
   Google Scholar
• Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet Lond Engl. 2020 Apr 25;395(10233):1374–81. doi:10.1016/S0140-6736(20)30325-1.
   Google Scholar
• Kim HS, Kang J, Hwang D, Han JK, Yang HM, Kang HJ, Koo B-K, Rhew JY, Chun K-J, Lim Y-H, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet Lond Engl. 2020 Oct 10;396(10257):1079–89. doi:10.1016/S0140-6736(20)31791-8.
   Google Scholar
• Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet Lond Engl. 2016 Oct 22;388(10055):2015–22. doi:10.1016/S0140-6736(16)31323-X.
   Google Scholar
• Savonitto S, Ferri LA, Piatti L, Grosseto D, Piovaccari G, Morici N, Bossi I, Sganzerla P, Tortorella G, Cacucci M, et al. Comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization. Circulation. 2018 Jun 5;137(23):2435–45. doi:10.1161/CIRCULATIONAHA.117.032180.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015 Mar 3;65(8):805–15. doi:10.1016/j.jacc.2014.11.053.
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015 Nov 19;373(21):2038–47. doi:10.1056/NEJMoa1503943.
   PubMed Web of Science ®Google Scholar
• Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, Hovasse T, Garot P, El Mahmoud R, Spaulding C, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet Lond Engl. 2018 Jan 6;391(10115):41–50. doi:10.1016/S0140-6736(17)32713-7.
   Google Scholar
• Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, et al. Polymer-based or polymer-free stents in patients at high bleeding risk. N Engl J Med. 2020 Mar 26;382(13):1208–18. doi:10.1056/NEJMoa1910021.
   PubMed Web of Science ®Google Scholar
• Mehran R, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, Hermiller J, Makkar RR, Neumann F-J, Saito S, et al. 3- or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. JACC Cardiovasc Interv. 2021 Sep 13;14(17):1870–83. doi:10.1016/j.jcin.2021.07.016.
   PubMed Web of Science ®Google Scholar
• Kirtane AJ, Stoler R, Feldman R, Neumann FJ, Boutis L, Tahirkheli N, Toelg R, Othman I, Stein B, Choi JW, et al. Primary results of the EVOLVE short DAPT study: evaluation of 3-month dual antiplatelet therapy in high bleeding risk patients treated with a bioabsorbable polymer-coated everolimus-eluting stent. Circ Cardiovasc Interv. 2021 Mar;14(3):e010144. doi:10.1161/CIRCINTERVENTIONS.120.010144.
   PubMed Web of Science ®Google Scholar